Kozak & Associates’s AstraZeneca AZN Stock Holding History

Kozak & Associates’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$46.5K	Hold	253	–	–	0.01%	150
2026 Q1	$51.2K	Buy	253 +3	+1%	+$578	0.01%	149
2025 Q4	$47.3K	Sell	250 -501	-67%	-$87.9K	0.01%	150
2025 Q3	$134K	Sell	751 -20	-3%	-$3.03K	0.03%	99
2025 Q2	$109K	Sell	771 -30	-4%	-$4.2K	0.02%	106
2025 Q1	$109K	Hold	801	–	–	0.03%	98
2024 Q4	$106K	Buy	801 +31	+4%	+$4.34K	0.02%	97
2024 Q3	$121K	Buy	770 +4	+0.5%	+$646	0.03%	97
2024 Q2	$118K	Hold	766	–	–	0.03%	91
2024 Q1	$118K	Buy	766 +12	+2%	+$1.59K	0.03%	92
2023 Q4	$101K	Hold	754	–	–	0.03%	102
2023 Q3	$102K	Buy	754 +24	+3%	+$3.28K	0.04%	100
2023 Q2	$95.3K	Hold	730	–	–	0.04%	109
2023 Q1	$101K	Hold	730	–	–	0.05%	111
2022 Q4	$99K	Hold	730	–	–	0.05%	109
2022 Q3	$81K	Hold	730	–	–	0.05%	113
2022 Q2	$96K	Hold	730	–	–	0.06%	108
2022 Q1	$89K	Hold	730	–	–	0.06%	123
2021 Q4	$89K	Hold	730	–	–	0.06%	123
2021 Q3	$87K	Buy	+730	New	+$85K	0.05%	121

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Kozak & Associates's AZN Position: Q2 2026 in Review

Kozak & Associates held its AstraZeneca (AZN) position steady in Q2 2026 at 253 shares worth $46.5K. The position accounts for 0.01% of the portfolio, ranked #150.

Kozak & Associates first reported a position in AZN in Q3 2021 and has held it in 20 quarters since. The position peaked at $134K in Q3 2025. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Kozak & Associates held 253 shares of AstraZeneca worth $46.5K as of Q2 2026.
Kozak & Associates left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.01% of Kozak & Associates's portfolio in Q2 2026, its #150 holding.
Kozak & Associates first reported a position in AstraZeneca in Q3 2021 and has held it in 20 quarters since.
Kozak & Associates's AstraZeneca position peaked at $134K in Q3 2025.
1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Kozak & Associates's 13F filing for Q2 2026, filed 2 Jul 2026.